NASDAQ · DYN
Healthcare · Biotechnology
$18.05
Up+$0.49 (+2.71%)
Updated Nov 4, 2026, 9:45 PM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · DYN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
DYN closed at $18.05 after 21 trading sessions, up 17.21% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $17.53 | $18.145 | $17.31 | $18.05 | 2.81M |
| Nov 2, 2026 | $16.81 | $17.35 | $16.71 | $17.30 | 2.91M |
| Oct 30, 2026 | $16.97 | $17.195 | $16.34 | $16.69 | 1.45M |
| Oct 29, 2026 | $17.20 | $17.59 | $16.75 | $17.04 | 1.43M |
| Oct 28, 2026 | $16.30 | $17.115 | $16.11 | $16.98 | 2.18M |
| Oct 27, 2026 | $15.80 | $16.97 | $15.73 | $16.94 | 3M |
| Oct 26, 2026 | $15.64 | $16.02 | $15.53 | $15.72 | 1.74M |
| Oct 23, 2026 | $15.915 | $15.915 | $15.315 | $15.62 | 2.13M |
| Oct 22, 2026 | $15.985 | $16.335 | $15.67 | $15.77 | 2.05M |
| Oct 21, 2026 | $16.33 | $16.73 | $15.91 | $16.07 | 1.79M |
| Oct 20, 2026 | $15.27 | $16.56 | $15.14 | $16.27 | 3.41M |
| Oct 19, 2026 | $14.45 | $15.375 | $14.45 | $15.23 | 3.35M |
| Oct 16, 2026 | $15.21 | $15.49 | $14.13 | $14.25 | 2.86M |
| Oct 15, 2026 | $15.15 | $15.47 | $15.04 | $15.29 | 2.07M |
| Oct 14, 2026 | $15.11 | $15.415 | $14.71 | $15.04 | 2.2M |
| Oct 13, 2026 | $15.97 | $15.99 | $15.28 | $15.30 | 3.34M |
| Oct 12, 2026 | $16.54 | $16.76 | $15.73 | $15.96 | 2.92M |
| Oct 9, 2026 | $16.41 | $17.31 | $16.36 | $16.64 | 3.57M |
| Oct 8, 2026 | $15.835 | $16.47 | $15.35 | $16.37 | 6.28M |
| Oct 7, 2026 | $15.40 | $16.115 | $15.245 | $15.97 | 3.49M |
| Oct 6, 2026 | $15.50 | $15.59 | $14.925 | $15.40 | 4.1M |
The latest Smart Investors Daily articles mentioning DYN.
Company
Market Activity
Research & News
DYN research
Company profile and research snapshot.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | Perform | — |
| Sep 30, 2026 | Chardan Capital | Buy | — |
| Sep 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 29, 2026 | Piper Sandler | Overweight | — |
| Sep 9, 2026 | Baird | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 28, 2026
Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.
Yahoo · Oct 22, 2026
WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 16 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity
Yahoo · Oct 8, 2026
Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.
Yahoo · Oct 7, 2026
Dyne Therapeutics (DYN) has drawn fresh attention after releasing one year efficacy and safety data from the Phase 1/2 ACHIEVE trial of DYNE-101 in myotonic dystrophy type 1, highlighting functional gains compared with baseline and natural history cohorts. Recent enthusiasm around Dyne Therapeutics has come against a sharply weaker tape, with the share price falling about 37% over the past month and 37% over 90 days. At the same time, the 1-year total shareholder return is 5.8% and the 3-year...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DYN.
